Assignee
BLUEPRINT MEDICINES CORP
US·59 granted patents·47 pending applications·593 citations·filing 2014–2025
Top patents by PatentIndex Score
106 records- 0198US10030005B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 24, 2018·38 cites·30 claims
- 0298US9695165B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jul 4, 2017·40 cites·20 claims
- 0398US9688680B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jun 27, 2017·40 cites·21 claims
- 0497US11279688B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2020·Granted Mar 22, 2022·5 cites·2 claims
- 0597US10000490B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jun 19, 2018·30 cites·12 claims
- 0697US10000496B2Compositions useful for treating disorders related to kit and PDGFRBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jun 19, 2018·32 cites·54 claims
- 0797US9994575B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jun 12, 2018·32 cites·20 claims
- 0897US9944651B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2017·Granted Apr 17, 2018·33 cites·24 claims
- 0997US9884861B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2016·Granted Feb 6, 2018·32 cites·7 claims
- 1097US9340514B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted May 17, 2016·43 cites·11 claims
- 1196US11827642B2Compositions useful for treating disorders related to KITBLUEPRINT MEDICINES CORP·Filed 2022·Granted Nov 28, 2023·2 cites·6 claims
- 1296US10807985B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2018·Granted Oct 20, 2020·7 cites·1 claims
- 1396US10227329B2Compounds useful for treating disorders related to RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 12, 2019·19 cites·21 claims
- 1496US10196436B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2018·Granted Feb 5, 2019·17 cites·1 claims
- 1596US9994552B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jun 12, 2018·31 cites·10 claims
- 1695US10584114B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2018·Granted Mar 10, 2020·13 cites·3 claims
- 1795US10183928B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jan 22, 2019·13 cites·47 claims
- 1895US10035789B2Compounds useful for treating disorders related to RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jul 31, 2018·31 cites·21 claims
- 1995US10017512B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 10, 2018·29 cites·26 claims
- 2094US11534441B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 27, 2022·3 cites·25 claims
- 2194US10829493B2Compositions and methods for treating KIT- and PDGFRA-mediated diseasesBLUEPRINT MEDICINES CORP·Filed 2020·Granted Nov 10, 2020·5 cites·41 claims
- 2294US10378063B2RAF1 fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Granted Aug 13, 2019·8 cites·6 claims
- 2394US10202365B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2016·Granted Feb 12, 2019·20 cites·15 claims
- 2493US11718602B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Aug 8, 2023·2 cites·8 claims
- 2593US10233186B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 19, 2019·16 cites·56 claims
- 2693US10221154B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2016·Granted Mar 5, 2019·11 cites·10 claims
- 2792US11273160B2RET inhibitor for use in treating cancer having a RET alterationBLUEPRINT MEDICINES CORP·Filed 2020·Granted Mar 15, 2022·5 cites·14 claims
- 2892US10774070B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2018·Granted Sep 15, 2020·6 cites·14 claims
- 2991US11999744B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2023·Granted Jun 4, 2024·2 cites·14 claims
- 3091US11970498B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2023·Granted Apr 30, 2024·1 cites·26 claims
- 3190US12042495B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Jul 23, 2024·1 cites·18 claims
- 3290US11046697B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2018·Granted Jun 29, 2021·5 cites·20 claims
- 3390US10669277B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2019·Granted Jun 2, 2020·9 cites·17 claims
- 3489US11932648B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Mar 19, 2024·1 cites·18 claims
- 3589US11872192B2RET inhibitor for use in treating cancer having a RET alterationBLUEPRINT MEDICINES CORP·Filed 2021·Granted Jan 16, 2024·2 cites·19 claims
- 3687US2024317757A1Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2023·Application pending·0 cites
- 3784US12060354B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2021·Granted Aug 13, 2024·1 cites·14 claims
- 3883US11634422B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2020·Granted Apr 25, 2023·1 cites·30 claims
- 3983US10875837B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2019·Granted Dec 29, 2020·1 cites·6 claims
- 4081US12545684B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Granted Feb 10, 2026·0 cites·20 claims
- 4181US12252494B2Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosisBLUEPRINT MEDICINES CORP·Filed 2022·Granted Mar 18, 2025·1 cites·7 claims
- 4280US2025289801A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Application pending·0 cites
- 4379US12595265B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2023·Granted Apr 7, 2026·0 cites·31 claims
- 4479US10407509B2NTRK2 fusionsBLUEPRINT MEDICINES CORP·Filed 2014·Granted Sep 10, 2019·3 cites·8 claims
- 4578US11964980B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2022·Granted Apr 23, 2024·0 cites·7 claims
- 4678US2026049080A1Wild type kit inhibitorsBLUEPRINT MEDICINES CORP·Filed 2025·Application pending·0 cites
- 4777US12448379B2Wild type kit inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Granted Oct 21, 2025·0 cites·33 claims
- 4877US2022315560A1Inhibitors of retBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 4974US2022213553A1Prkc fusionsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 5074US2021284645A1Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2020·Application pending·0 cites
Showing the top 50 of 106 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →